ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Madrigal Pharmaceuticals, Inc. ?
1
Positive results in Mar 26
- NET SALES(Q) At USD 311.34 MM has Grown at 126.84%
- OPERATING CASH FLOW(Y) Highest at USD -268.1 MM
- NET PROFIT(HY) Higher at USD -152.97 MM
2
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 70.17%, its profits have risen by 38.7%
3
High Institutional Holdings at 100%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
4
Market Beating performance in long term as well as near term
- Along with generating 70.17% returns in the last 1 year, the stock has outperformed S&P 500 in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Madrigal Pharmaceuticals, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Madrigal Pharmaceuticals, Inc. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Madrigal Pharmaceuticals, Inc.
70.17%
1.74
50.08%
S&P 500
22.99%
1.78
12.93%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
294.82%
EBIT Growth (5y)
-11.34%
EBIT to Interest (avg)
-116.13
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.03
Sales to Capital Employed (avg)
0.44
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
19.44
EV to EBIT
-36.88
EV to EBITDA
-37.06
EV to Capital Employed
-245.61
EV to Sales
11.55
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-47.37%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bearish
Bullish
Dow Theory
No Trend
No Trend
OBV
Mildly Bullish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend18What is working for the Company
NET SALES(Q)
At USD 311.34 MM has Grown at 126.84%
OPERATING CASH FLOW(Y)
Highest at USD -268.1 MM
NET PROFIT(HY)
Higher at USD -152.97 MM
CASH AND EQV(HY)
Highest at USD 1,806.58 MM
-13What is not working for the Company
INTEREST(HY)
At USD 16.12 MM has Grown at 137.17%
RAW MATERIAL COST(Y)
Grown by 5.44% (YoY
DEBT-EQUITY RATIO
(HY)
Highest at -86.6 %
PRE-TAX PROFIT(Q)
Fallen at -28.88%
NET PROFIT(Q)
Fallen at -28.88%
Here's what is working for Madrigal Pharmaceuticals, Inc.
Net Sales
At USD 311.34 MM has Grown at 126.84%
Year on Year (YoY)MOJO Watch
Near term sales trend is extremely positive
Net Sales (USD MM)
Operating Cash Flow
Highest at USD -268.1 MM
in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Cash and Eqv
Highest at USD 1,806.58 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents
Here's what is not working for Madrigal Pharmaceuticals, Inc.
Interest
At USD 16.12 MM has Grown at 137.17%
over previous Semi-Annual periodMOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (USD MM)
Pre-Tax Profit
Fallen at -28.88%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is negative
Pre-Tax Profit (USD MM)
Net Profit
Fallen at -28.88%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is negative
Net Profit (USD MM)
Debt-Equity Ratio
Highest at -86.6 %
in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
Raw Material Cost
Grown by 5.44% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
